Siemens completes takeover of Bayer’s Diagnostic Division
10 January 2007 Erlangen, Germany & Tarrytown, New York. Siemens
Medical Solutions has completed the acquisition of Bayer Healthcare’s
diagnostic division.
Bayer Diagnostics and Diagnostic Products Corporation (DPC), acquired in
July 2006, were merged into a single business unit on January 1, 2007. The
new entity, “Siemens Medical Solutions Diagnostics,” is a wholly owned
subsidiary of Siemens Medical Solutions USA, Inc. and employs more than
8,000 people worldwide. Siemens Medical Solutions Diagnostics, headquartered
in Tarrytown, N.Y. and Los Angeles, CA, holds the second position in the
worldwide immunodiagnostics market. This new business is integral to
Siemens’ overall strategy to help its customers improve workflow throughout
the healthcare enterprise. Bringing together the entire medical imaging,
laboratory diagnostics and clinical IT value chain under one roof puts
Siemens in a unique position to leverage trendsetting technologies for an
improved quality of patient care at reduced costs. DPC and Bayer Diagnostics
generated cumulative sales of €1.8 billion in fiscal 2005 (Dec. 31). The
cost for both acquisitions totalled €5.7 billion. “With the acquisitions
of DPC and Bayer Diagnostics, we invested heavily in a future oriented and
growing market in the health care sector. We see tremendous potential for
Siemens Medical Solutions Diagnostics and have high expectations for the new
unit,” said Klaus Kleinfeld, CEO of Siemens AG. “Siemens is the world’s
only full-service diagnostics company – bringing together for the first time
a unique set of products and services that will speed the development of
molecular medicine capabilities, and improve the efficiency and quality of
healthcare,” said Erich Reinhardt, Ph.D., member of the Managing Board of
Siemens AG and president and CEO of Siemens Medical Solutions. “Siemens has
anticipated the convergence of social, economic and political challenges
facing the healthcare industry, and we alone have responded and developed
this comprehensive portfolio of innovative solutions, from medical imaging
and healthcare information technology (IT), to management consulting and,
now, laboratory diagnostics,” Reinhardt added. Siemens Medical Solutions
Diagnostics maintains leading market positions in the fields of clinical
chemistry, patient tests, laboratory automation and blood cell diagnostics
(haematology). The company also develops solutions for the rapidly growing
markets of molecular diagnostics and gene analysis with the aim of
continuing to improve personalized medicine. The company will also offer a
comprehensive portfolio for the diagnosis and treatment of a wide array of
illnesses such as adrenal/pituitary dysfunction, allergy, anaemia, diabetes
and reproductive and thyroid disorders, infectious diseases, kidney
ailments, cardiology, oncology, diabetes and virology. Siemens Medical
Solutions Diagnostics’ top management is comprised of managers with many
years’ experience in the health care business: Anthony Bihl, previous
president of the Diagnostics division of Bayer Healthcare LLC, has been
named as CEO. Sid Aroesty, who served as president and COO of DPC, was
nominated COO of the new business; and Jochen Schmitz, previous CFO of the
Siemens Medical Solutions Molecular Imaging division, will assume the CFO
role. To top
|
|